CD36 and neoplasm: Gross observation and hematoxylin and eosin (HE) staining of lung metastases in mice demonstrated that ROSI administration reduced the number of tumor nodules, while SSO administration increased the number of tumor nodules (Figure 8G,H), thereby confirming the in vivo antimetastatic effect of CD36 agonists on TNBC cells.